MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
Ferreri
A J M
AJ
Medical Oncology Unit, San Raffaele H Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy. ferreri.andres@hsr.it
Dell'Oro
S
S
Foppoli
M
M
Bernardi
M
M
Brandes
A A
AA
Tosoni
A
A
Montanari
M
M
Balzarotti
M
M
Spina
M
M
Ilariucci
F
F
Zaja
F
F
Stelitano
C
C
Bobbio
F
F
Corazzelli
G
G
Baldini
L
L
Ponzoni
M
M
Picozzi
P
P
Caligaris Cappio
F
F
Reni
M
M